RxDoctor Payments Data

Kevin Terry

Podiatrist · Lutherville, MDNPI 1699812198

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.8% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Smith+Nephew at 30.5% of the total. Reporting peaked in 2019 at $485 and has fallen 76.3% since, to $115 in 2025.

$1,911in general payments, 2019–2025

Across 55 payments — averaging $34.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$582
  • Osteomed LLC$344
  • Amgen$237
  • Molecular Biologicals, Inc$234
  • Keswick Pharmaceuticals LLC$108
  • Melinta Therapeutics, LLC$80
  • plus $327 from 14 others

What the payments were for

  • Food & beverage$1,85097%
  • Education$623%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,911 in reported general payments places this provider in the 70th percentile of 183 podiatrist providers in Maryland.

See all podiatrist providers in Maryland

Medicare billing

Part B allowed, 2024
$209,263
Medicare patients
1,004
Services billed
3,635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciclopirox133$2,972
Ketoconazole75$2,166
Ammonium Lactate34$902
Mupirocin61$560
Celecoxib16$508
Doxycycline Hyclate32$338
Triamcinolone Acetonide17$262
CefuroximeCefuroxime Axetil13$245
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav16$168
Pregabalin15$87
Terbinafine Hcl12$73
Meloxicam20$36
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$26

Paid to pharmacies, not to this prescriber.

Other podiatrist in Lutherville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →